The Impact of Culturing the Organ Preservation Fluid on Solid Organ Transplantation: A Prospective Multicenter Cohort Study by Oriol, I. et al.
M A J O R  A R T I C L E
Impact of Culturing the Organ PF on SOT • ofid • 1
Open Forum Infectious Diseases
 
Received 19 February 2019; editorial decision 4 April 2019; accepted 17 April 2019.
Correspondence: I. Oriol Bermúdez, Infectious Diseases Department, Hospital Universitari 
de Bellvitge, Feixa llarga s/n. 08907, L’Hospitalet de Llobregat, Barcelona, Spain 
(isaoriolbermudez@gmail.com).
Open Forum Infectious Diseases®
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/ofid/ofz180
The Impact of Culturing the Organ Preservation Fluid on 
Solid Organ Transplantation: A Prospective Multicenter 
Cohort Study
I. Oriol,1,2,3 N. Sabe,1,2,3 J. Càmara,4,5 D. Berbel,4,5 M. A. Ballesteros,6 R. Escudero,7 F. Lopez-Medrano,8,9 L. Linares,3,10 O. Len,11,12 J. T. Silva,8,9,13 E. Oliver,14  
L. Soldevila,1 S. Pérez-Recio,1 L. L. Guillem,1 D. Camprubí,1 L. LLadó,15 A. Manonelles,16 J. González-Costello,17 M. A. Domínguez,2,4,18 M. C. Fariñas,19  
N. Lavid,20 C. González-Rico,19 L. Garcia-Cuello,19 F. Arnaiz de las Revillas,19 J. Fortun,7 J. M. Aguado,8,9 C. Jimenez-Romero,8,9 M. Bodro,3,10 M. Almela,3,10  
D. Paredes,3,10 A. Moreno,3,10 C. Pérez-Cameo,12,21 A. Muñoz-Sanz,13 G. Blanco-Fernández,22 J. A. Cabo-González,23 J. L. García-López,24 E. Nuño,24 and  
J. Carratalà1,2,3
1Infectious Disease Department, Hospital Universitari de Bellvitge – IDIBELL; L’Hospitalet de Llobregat, Barcelona, Spain; 2Spanish Network for Research in Infectious Diseases (REIPI); 3Clinical 
Science Department, Faculty of Medicine, University of Barcelona, Barcelona; 4Microbiology Department, Hospital Universitari de Bellvitge-Universitat de Barcelona-IDIBELL, L’Hospitalet de 
Llobregat, Spain; 5CIBER de Enfermedades Respiratorias (CIBERes), Madrid, Spain; 6Intensive Care Unit, Marqués de Valdecilla Hospital, University of Cantabria, IDIVAL, Santander, Spain; 
7Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. IRYCIS; 8Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación 
Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain; 9School of Medicine, Universidad Complutense, Madrid, Spain; 10Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, 
Spain; 11Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 12Universitat Autònoma de Barcelona, Barcelona, Spain; 13Department of Infectious Diseases, 
Hospital Universitario de Badajoz, Spain; 14Donor Coordination Unit, Bellvitge University Hospital, Barcelona, Spain; 15Liver Transplant Unit, Hospital Universitari de Bellvitge, L’Hospitalet de 
Llobregat (Barcelona), Spain; 16Department of Nephrology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona), Spain; 17Department of Cardiology, Hospital Universitari de 
Bellvitge, L’Hospitalet de Llobregat (Barcelona), Spain; 18Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona; 
19Infectious Diseases Unit, Marqués de Valdecilla Hospital, University of Cantabria, IDIVAL, Santander, Spain; 20Donor Coordination Unit, Marqués de Valdecilla Hospital, University of Cantabria, 
IDIVAL, Santander, Spain; 21Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 22Liver Transplant Unit, Hospital Universitario de Badajoz, Spain; 23Kidney 
Transplant Unit, Hospital Universitario de Badajoz, Spain; 24Donor Coordination Unit, Hospital universitario de Badajoz, Spain
Background. We analyzed the prevalence, etiology, and risk factors of culture-positive preservation fluid and their impact on 
the management of solid organ transplant recipients.
Methods. From July 2015 to March 2017, 622 episodes of adult solid organ transplants at 7 university hospitals in Spain were 
prospectively included in the study.
Results. The prevalence of culture-positive preservation fluid was 62.5% (389/622). Nevertheless, in only 25.2% (98/389) of the cases 
were the isolates considered “high risk” for pathogenicity. After applying a multivariate regression analysis, advanced donor age was the 
main associated factor for having culture-positive preservation fluid for high-risk microorganisms. Preemptive antibiotic therapy was 
given to 19.8% (77/389) of the cases. The incidence rate of preservation fluid–related infection was 1.3% (5 recipients); none of these 
patients had received preemptive therapy. Solid organ transplant (SOT) recipients with high-risk culture-positive preservation fluid re-
ceiving preemptive antibiotic therapy presented both a lower cumulative incidence of infection and a lower rate of acute rejection and 
graft loss compared with those who did not have high-risk culture-positive preservation fluid. After adjusting for age, sex, type of trans-
plant, and prior graft rejection, preemptive antibiotic therapy remained a significant protective factor for 90-day infection.
Conclusions. The routine culture of preservation fluid may be considered a tool that provides information about the contami-
nation of the transplanted organ. Preemptive therapy for SOT recipients with high-risk culture-positive preservation fluid may be 
useful to avoid preservation fluid–related infections and improve the outcomes of infection, graft loss, and graft rejection in trans-
plant patients.
Keywords. preemptive antibiotic therapy; preservation fluid; preservation fluid–related infection; solid organ transplantation.
In spite of many advances, early postoperative infections re-
main a significant cause of morbidity and mortality among 
solid organ transplant (SOT) recipients [1]. Therefore, the 
prevention, diagnosis, and management of infections have be-
come one of the main challenges of transplantation.
Early post-transplant infections are usually derived from the 
donor or recipient or from technical complications of surgery 
[2]. The organ donated may be contaminated either by an in-
fection from the donor or as a consequence of the manipulation 
of the organ in the time between extraction and implantation 
[3–6]. Moreover, due to its biochemical characteristics, the 
organ preservation fluid (PF) can keep microorganisms alive 
and also facilitate their growth [7]. This is why some transplant 
centers now take intra-operative cultures of the PF to detect 
infection promptly and avoid its transmission to the recipient. 
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However, there are no widely accepted guidelines for the evalu-
ation of PF or for the use of prophylactic antibiotics [8]. Reliable 
evidence in support of this practice is scarce and is mainly based 
on retrospective studies and case reports.
The role of culture-positive PF in the management of trans-
plant recipients has not been fully elucidated. In fact, it is not 
clear whether the organ PF should be cultured during the trans-
plant procedure or whether preemptive antibiotic treatment 
(PE-T) is required in SOT recipients with culture-positive PF. 
In a recent meta-analysis, our group found a high incidence of 
culture-positive PF, and although few SOT recipients with PF 
cultures are positive for pathogenic microorganisms, they may 
develop a PF-related infection with high mortality [9]. However, 
this meta-analysis was based on the few studies available, which 
were mainly retrospective; indeed, prospective studies of this 
subject are lacking.
This prospective multicenter study with a large patient popu-
lation aims to analyze the incidence, etiology, and risk factors of 
culture-positive PF and their clinical impact in order to indicate 
areas for improvement in the management of SOT recipients.
METHODS
Setting and Study Population
We conducted a prospective multicenter cohort study at 7 ter-
tiary university referral hospitals in Spain with active transplan-
tation programs (kidney, liver, heart, lung, or pancreas). From 
July 2015 to March 2017, episodes of SOT in adults were in-
cluded if the patients or legal surrogates provided written in-
formed consent. Episodes in which the PF was not cultured, in 
which the recipient died/lost the organ donated within the first 
24 hours, or in which informed consent was not provided were 
not included.
The primary study end point was to assess the incidence 
rate of PF-related infections. Secondary end points included 
the prevalence of culture-positive PF, the incidence risk ratio 
of PF-related infection between SOT recipients who received 
PE-T and those who did not, and the cumulative incidence of 
bacterial infections at 90 days and other outcomes at 90 days: 
graft loss, acute graft rejection (AGR), and mortality.
Data regarding the transplant surgery, as well as the baseline 
characteristics of SOT donors and SOT recipients, were care-
fully recorded in an electronic database. All patient data were 
entered anonymously. To reduce measurement errors, a process 
of data quality evaluation was used.
Clinical follow-up was performed daily during the post-
transplant hospital admission period and then periodically 
at outpatient appointments, with a post-transplant follow-up 
period of 3 months. There was no formal or institutional con-
sensus regarding PE-T; the choice was left to the discretion of 
each attending physician. In cases where PE-T was administered, 
it was started as soon as the PF culture was found to be positive 
and was adapted to the resistance profile of the microorganism 
identified. Similarly, SOT patients received perioperative anti-
bacterial prophylaxis, as well as prophylaxis for opportunistic 
infections, in accordance with the protocol of each center.
The study was approved by the ethics committees of all 
participating institutions and conformed to the STROBE 
checklist.
Definitions
Culture-positive PF was defined as growth of any microor-
ganism in the PF culture. PF cultures in which the following 
microorganisms grew were considered to be “high risk”: 
gram-negative bacilli, Staphylococcus aureus, β-hemolytic 
streptococci, Streptococcus pneumoniae, enterococci, any spore-
forming anaerobic gram-positive bacteria, Bacteroides species, 
and Candida spp. All the other culture-positive PF were clas-
sified as “low risk,” including coagulase-negative staphylococci 
(CNS), Corynebacterium spp., and Streptococcus viridans group 
[5]. PE-T was considered as an immediate post-transplant 
targeted antibiotic or antifungal treatment against the isolates of 
culture-positive PF without any clinical signs of active infection 
in the recipient. PF-related infection was defined as documented 
infection in the recipient by the same microorganism isolated in 
the PF culture. Infections were defined according to the Centers 
for Disease Control and Prevention/National Healthcare Safety 
Network guidelines [10]. Multidrug resistance (MDR) was de-
fined as acquired nonsusceptibility to at least 1 agent in 3 or 
more antimicrobial categories [11]. AGR was considered to be 
present when proven by biopsy, and 90-day mortality was de-
fined as death by any cause within the first 90  days after the 
onset of SOT.
Microbiological Studies
Grafts were routinely preserved, mainly in 1 of the following 
PFs: Celsior, Wisconsin, Perfadex, and Custodiol. PF culture 
was obtained under sterile conditions just before implantation.
PF samples were processed by the BACTEC FX method 
(Becton-Dickinson Microbiology Systems, Sparks, MD). The 
inoculated bottles were incubated for 5  days at 35ºC before 
being discharged. Microbial identification was performed using 
commercially available panels (MicroScan, Beckman Coulter; 
Brea, CA; or Vitek, Biomérieux, Marcy-L’Étoile, France; or by 
matrix-assisted laser desorption ionization [MALDI-TOF], 
Bruker Daltonik, Bremen, Germany). Antibiotic suscepti-
bility was tested using the microdilution method following 
EUCAST guidelines [12]. Molecular typing was performed 
through pulse field gel electrophoresis after restriction with 
XbaI (enterobacteriaceae) or SmaI (staphylococci) following 
the criteria described by Tenover [13]. The screening of MDR 
phenotypes including methicillin-resistant S. aureus, ampicillin-
resistant enterococci, extended-spectrum β-lactamase produc-
tion (ESBL), and carbapenemase production was performed in 
accordance with EUCAST recommendations.
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Statistical Analysis
We estimated the prevalence of culture-positive PF, the in-
cidence rate of PF-related infections, the incidence risk ratio, 
and the risk difference of PF-related infections between SOT 
recipients who received PE-T and those who did not, with con-
fidence intervals.
To compare episodes of SOT by the result of the culture-
positive PF, we used the chi-square test with continuity cor-
rection for categorical variables and the Student t test and 
Mann-Whitney U test for continuous variables. Multivariate 
conditional regression analysis of factors potentially associated 
with high-risk culture-positive PF was performed, including 
all statistically significant variables in the univariate analysis, 
sex and age, and all clinically important variables regardless of 
whether they were statistically significant. Odds ratio (ORs) and 
95% confidence interval (CIs) were calculated.
Cumulative incidence of bacterial infection among SOT 
recipients, depending on the result of their PF culture and 
the decision to give PE-T, was estimated in a competing risk 
model in which death and graft loss were modeled as competing 
events. Patients included were censored at the time of (a) death, 
(b) graft loss, or (c) end of study follow-up. We tested for 
differences between groups using Fine-Gray regression models 
[14]. Other secondary outcome variables were compared using 
the Fisher exact test.
 All the statistical management was performed using STATA 
statistical software, release 13.0 (STATA Corp., College Station, 
TX). All statistical tests were 2-tailed, and the threshold of sta-
tistical significance was P < .05.
RESULTS
During the study period, 622 episodes of SOT were prospec-
tively included (kidney 362, liver 166, lung 51, heart 32, and 
multi-organ 11). Baseline demographic and clinical characteris-
tics of SOT donors and SOT recipients, including the operation-
related data, are summarized in Table 1.
The prevalence of culture-positive PF was 62.5% (389/622). 
Most of the isolates were considered “low-risk” microorganisms 
(291/622), and only 15.8% (98/622) were considered “high-risk” 
pathogens. Only in 3 cases were the isolates considered MDR. 
The microorganisms isolated are detailed in full in Table 2.
Table 3 summarizes the risk factors for high-risk culture-
positive PF. After applying a backward stepwise logistic regres-
sion model, advanced donor age (OR, 1.88; 95% CI, 1.16–3.05) 
was found to be an independent risk factor for culture-positive 
PF by high-risk microorganisms.
The median length of antibiotic prophylaxis (interquartile 
range [IQR]) was 24 (24–48) hours. The isolated microorganisms 
were sensitive to the antibiotic prophylaxis administered 
during transplantation in 74% of high-risk SOT recipients. 
PE-T covering the PF isolate was given to 19.8% (77/389) of 
the culture-positive PF cases (51 due to high-risk and 26 due 
to low-risk microorganisms). The percentage of high-risk cases 
that received PE-T varied according to the transplanted organ: 
13% (2/15) in lung transplant, 54% (18/33) in liver transplant, 
60% (28/47) in kidney transplant, and 100% (1/1) in heart 
transplant. The median length of PE-T (IQR) was 6 (4–12) days. 
The median duration of PE-T (IQR) was different according to 
the microorganisms isolated in the PF culture: 5 (4–7) days for 
CNS isolation, 5 (3–8) days for S. aureus isolation, 4 (3–18) days 
Table 1. Baseline Demographic and Clinical Characteristics of SOT 
Donors and SOT Recipients, Including Surgery-Related Data
Characteristics n = 622
Donor features  
 Age, y 61 (49–72)
 Male sex 348 (56.0)
 Living donors 39 (6.3)
 Brain death donors 449 (72.2)
 Donors after circulatory death 134 (21.5)
 Length of ICU stay, d 2 (1–5)
 Need for vasoactive drugs 412 (66.2)
 Prior colonization by resistant microorganisms or fungi 6 (1)
 Donor infection 112 (18.0)
 Respiratory tract infection 85 (13.7)
 Urinary tract infection 7 (1.1)
 Central nervous system 7 (1.1)
 Other 13 (2.1)
 Donor positive cultures 87 (14.0)
 Surgery-related features  
 Red blood cell transfusion 205 (33.0)
 Fresh-frozen plasma transfusion 94 (15.1)
 Platelet transfusion 93 (15.0)
 Cold ischemia time, min 470 (280–1055)
  KT 940 (320–1260)
  LT 376 (285–480)
  HT 195 (151–225)
  PT 350 (295–405)
 Length of surgery, min 200 (150–335)
  KT 155 (135–185)
  LT 375 (313–430)
  HT 312 (244–413)
  PT 300 (250–360)
 Length of antibiotic prophylaxis, h 24 (24–48)
Type of PF  
 Celsior 356 (57.2)
 Wisconsin 116 (18.7)
 Perfadex 43 (6.9)
 Custodiol 22 (3.5)
 Other 85 (13.7)
Recipient features  
 Male sex 416 (66.9)
 Age 59 (51–66)
 Prior colonization by resistant microorganisms or fungi 30 (4.8)
All data are presented as No. (%) or median (interquartile range).
Abbreviations: HT, heart transplant; ICU, intensive care unit; KT, kidney transplant; LT, liver 
transplant; MT, multi-organ transplant; PF, preservation fluid; PT, lung transplant; SOT, solid 
organ transplant.
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for Enterococci, 8 (5–13) days for Enterobacteriaceae, 14 (6–17) 
days for Pseudomonas spp., and 13 (13–46) days in those SOT 
recipients with growth of Candida spp. in their PF.
PF-related infection occurred in 5 recipients, representing a 
cumulative incidence of 1.3% of SOT recipients with culture-
positive PF. The median time from transplantation to the onset 
of PF-related infection was 6  days. The clinical characteris-
tics of PF-related infections are summarized in Table 4. In the 
case of Enterobacter cloacae, PF-related infection clonality was 
demonstrated between the strains of the PF culture and the bio-
logical sample by the molecular epidemiology study.
The incidence risk ratio of PF-related infection between 
treated and untreated SOT recipients could not be calculated 
because no PF-related infections were detected in the PE-T 
group. No statistically significant differences were detected 
when analyzing the difference in risk of PF-related infection 
between treated and untreated culture-positive PF, nor when 
analyzing the low-risk group separately. However, the difference 
in risk of PF-related infection due to high-risk pathogens be-
tween patients who received PE-T and those who did not was 
8.5% (95% CI, 0.5%–16.5%; P = .033).
Figure 1 shows the cumulative incidences of infection in SOT 
recipients depending on the result of the PF culture and the de-
cision to carry out PE-T.
SOT recipients with culture-positive PF experienced a 
higher cumulative incidence of infection than the other group 
(Supplementary Table 1). Analyzing only SOT recipients with 
culture-positive PF, the 90-day cumulative incidence of in-
fection was lower in the PE-T group. Likewise, among SOT 
recipients with culture-positive PF high-risk microorganisms, 
the 90-day cumulative incidence of infection was lower in the 
PE-T group. No differences between groups were detected in 
the low-risk group.
After adjusting for sex, age of SOT recipient, type of trans-
plant, and prior episode of AGR, the Fine-Gray analyses re-
vealed that SOT recipients with culture-positive PF by high-risk 
microorganisms receiving PE-T had a lower cumulative inci-
dence of infection (subhazard ratio,  0.46; 95% CI, 0.24–0.88) 
(Supplementary Table 2)
There were no significant differences either in the rate of 
ESBL-producing strains (25.9% vs 16.2%, P = .227) or in MDR 
isolates (7.4% vs 6.9%, P = .929) between the infections in SOT 
recipients who received PE-T and those who did not.
The Supplementary Data (Supplementary Table 3) show 
the comparison of other outcomes between SOT recipients 
depending on the result of the PF culture and the decision to 
carry out PE-T. SOT recipients with culture-positive PF had 
a higher rate of AGR and mortality than those with culture-
negative PF. Among SOT recipients with culture-positive 
PF, those who received PE-T had a lower risk of AGR. SOT 
recipients with culture-positive PF high-risk microorganisms 
who received PE-T experienced a lower frequency of AGR and 
graft loss than those who did not. No differences in outcomes 
between groups were detected in the low-risk group. No 
adjusted analysis was applied due to the small number of events.
DISCUSSION
This prospective multicenter cohort study is the largest carried 
out so far to analyze the incidence rate and outcomes of culture-
positive PF. We found a high incidence of culture-positive PF, 
although high-risk microorganisms were isolated in only 15.8% 
of the cases. Although prior data were mainly derived from 
retrospective cohorts and showed a wide variability between 
studies, our results are similar to those of previous prospective 
studies and support their findings [4, 15].
Advanced donor age was the main associated factor for PF that 
was culture-positive for high-risk microorganisms. Previous 
studies have hinted at an association between older donors and 
PF contamination but have been unable to demonstrate statis-
tical significance in their multivariate analyses. Unlike Cerutti 
Table 2. Microorganisms Isolated in the PF Culture of SOT
Culture-Positive PF (N = 389) No. (%)
High riska 98 (15.8)
Monomicrobial 71 (11.4)
Gram-positive bacteria Staphylococcus aureus 19 (4.9)
Enterococcus faecalis 7 (1.8)
Enterococcus faecium 2 (0.5)
Streptococcus pneumoniae 1 (0.2)
Streptococcus agalactiae 1 (0.2)
Gram-negative bacilli Escherichia coli 10 (2.6)
Enterobacter cloacae 5 (1.3)
Klebsiella spp. 4 (1.0)
Pseudomonas spp. 3 (0.8)
Serratia spp. 2 (0.5)
Haemophilus influenzae 2 (0.5)
Otherb 10 (2.6)
Anaerobes Bacteroides spp. 1 (0.2)
 Fungi Candida spp.c 4 (1.0)
Polymicrobial (high-risk +/- low-risk isolates) 27 (6.9)
Low riskd 291 (46.8)
Monomicrobial 243 (39.1)
Gram-positive bacteria CNS 225 (57.8)
Othere 15 (3.9)
Anaerobes Otherf 3 (0.5) 
Polymicrobial (only low-risk microorganisms) 48 (12.3)
Abbreviations: CNS, coagulase-negative staphylococci; CP, culture positive; PF, preserva-
tion fluid.
aHigh risk: gram-negative bacilli, Staphylococcus aureus, β-hemolytic Streptococcus spe-
cies, Streptococcus pneumoniae, Enterococci, Bacteroides, any spore-forming anaerobic 
gram-positive bacteria, and Candida spp.
bOther gram-negative bacilli: Citrobacter freundii (1), Burkholderia cepacia (1), 
Stenotrophomonas maltophilia (1), Cupriavidus gilardii (1), Hafnia alvei (1), Raultella 
planticola (1), Rothia mucilaginosa (1), other nonspecified gram-negative bacilli (3).
cCandida spp.: C. glabrata (2), C. albicans (1), C. tropicalis (1).
dAll microorganisms except those classified as high risk.
eOther gram-positive bacteria: viridans group streptococci (3), Bacillus cereus (2), 
Corynebacterium spp. (3), Lactobacillus (1), Micrococcus (3), Aerococcus viridans (1), other 
(2).
fAnaerobes: Prevotella (1), Bacteroides (1), Propionibacterium (1), Peptoniphilus harei (1).
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et al., we did not find an association between prolonged ICU 
stay and fluid contamination [7]. Interestingly, Sotiropoulos 
et al. analyzed data from 976 SOT donors and concluded that 
only donor leukocyte count was independently associated with 
contamination of the PF in SOT [16]. Regrettably, we did not 
include this variable in our analysis.
In our study, PF-related infections were detected in only 
1.3% of all SOT recipients with culture-positive PF, although 
the rate increased to 8.5% in the case of SOT recipients with 
high-risk culture-positive PF without PE-T. These rates are 
consistent with previous reports [17–20]. The high incidence 
of culture-positive PF and the low rate of PF-related infec-
tion are the reasons why some authors do not recommend 
routine PF culture; they argue that the benefit of treatment 
is low and that the risk of selecting resistant microorganisms 
may be increased [15, 21]. Nevertheless, the mortality rate of 
PF-related infections reported in other studies [7, 22, 23] has 
encouraged some authors to recommend a short course of 
PE-T in those SOT recipients with growth of microorganisms 
in their PF culture [24–26].
We did not detect any PF-related mortality. This conflicting 
result may be explained, at least in part, by the fact that we did 
not detect any PF-related infection by Candida spp., whose 
mortality rate (and the rate of graft loss described in case series 
and cohort studies) is between 50% and 100% of cases [7, 26–
28]. The prospective nature of the study may have contributed 
to the greater diagnostic sensitivity and to the earlier initiation 
of treatment.
A striking finding of this study was the fact that SOT 
recipients with culture-positive PF had worse outcomes than 
those with culture-negative PF. The difference in mortality was 
at the limit of statistical significance. Our results confirm pre-
vious findings by Yansouni et al., who in a retrospective series 
detected a greater number of infections in SOT recipients with 
culture-positive PF and a higher mortality rate in liver trans-
plant recipients with culture-positive PF [5]. In contrast, Janny 
Table 3. Univariate and Multivariate Analyses of Factors Associated With High-risk Culture-Positive PF
Variables
High-risk PFa  
(n = 98, 15.6%)
Low-riskb or Culture-Negative PF 
(n = 524, 84.2%) P Value
Adjusted OR  
(95% CI) P Value
Sex of donors (male) 53 (54.1) 295 (56.1) .656   
Type of donation   .141   
Living donors 10 (10.2) 29 (5.5)    
Brain death donors 73 (74.5) 374 (71.4)    
Donation after circulatory death 15 (15.3) 119 (22.7)    
Type of transplant      
KT 47 (48.0) 315 (60.1) .025 0.51(0.11–2.51)  .411
LT 33 (33.7) 133 (25.4) .089 0.86 (0.17–4.27)  .852
HT 1 (1.0) 31 (5.9) .044 0.15 (0.01–1.86) .140
PT 15 (15.3) 36 (6.9) .005 1.77 (0.34–9.31)  .501
MT 2 (2.0) 9 (1.7) .824   
Donor infection 12 (12.2) 100 (19.2) .103   
Mean ischemia time 578 (485–672) 678 (603–753) .259   
Advanced donor agec 81 (82.7) 383 (73.1) .046 1.88 (1.16–3.05) .010
ICU days of donor 3.1 (2.3–3.9) 3.6 (3.2–3.9) .317   
All data are presented as No. (%) or median (interquartile range).
Abbreviations: CI, confidence interval; HT, heart transplant; ICU, intensive care unit; KT, kidney transplant; LT, liver transplant; MT, multi-organ transplant; OR, odds ratio; PF, preservation 
fluid; PT, lung transplant. 
aHigh risk: gram-negative bacilli, Staphylococcus aureus, β-hemolytic Streptococcus species, Streptococcus pneumoniae, Enterococci, Bacteroides, any spore-forming anaerobic gram-pos-
itive bacteria, and Candida spp.
bAll microorganisms except those classified as high risk.
cDonor older than 60 years.




Sex of  
SOT  
Recipient
Age of  
Recipient, y




Isolated Type of Infection








1 LT Male 47 5 E. faecium Intra-abdominal infection 6 No No Yes No
2 HT Male 19 7 S. epidermidis Surgical site infection 14 No No Yes No
3 PT Female 58 28 S. aureus Respiratory tract infection 11 Yes No No No
4 PT Male 28 6 E. cloacae Respiratory tract infection 10 Yes No No No
5 PT Male 64 2 S. marcescens Respiratory tract infection 90 No No No No
Abbreviations: AGR, acute graft rejection; ICU, intensive care unit; HT, heart transplant; LT, liver transplant; PT, lung transplant; SOT, solid organ transplant.
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et  al. did not detect significant differences between culture-
positive and culture-negative PF bacteremia, although this 
may have been due to the small sample size in their study [27]. 
Likewise, Chaim et  al. detected a higher frequency of AGR 
among SOT recipients with culture-positive PF than in those 
with culture-negative PF [22]. An increase in the frequency of 
AGR is probably seen when immunosuppressive treatment is 
reduced in order to  avoid post-transplant infection. However, at 
present little is known about the relation of rejection and infec-
tion, and studies addressing this issue are lacking.
The reasons why SOT recipients of an organ with culture-
positive PF have worse outcomes have not been established. 
However, the result of the PF culture might be considered as 
an overall indicator of the quality of the SOT (including the 
donated organ and the transplant procedure).
Our results show that PE-T only improves the outcomes of 
infection, graft loss, and AGR in the case of high-risk culture-
positive PF. Furthermore, the administration of PE-T in these 
SOT recipients did not increase the percentage of ESBL isola-
tion and MDR strains in subsequent infections. It should be 
noted that the median duration of PE-T was less than a week, 
and the median of transplant antibiotic prophylaxis did not 
reach 2 days.
Among the strengths of this study are its prospective design, 
the inclusion of the largest number of SOT episodes described 
so far, and the fact that the study replicates usual clinical prac-
tice. Nevertheless, our research has some limitations that 
should be noted. We analyzed a heterogeneous group of SOT 
recipients, who may have had their own specific incidence rates 
of culture-positive PF and infection. Moreover, length of PE-T 
was not preestablished. Furthermore, we were unable to per-
form molecular epidemiology studies in most of the cases that 
were considered PF-related infections.
In conclusion, the routine culture of the organ preservation 
fluid may be considered as a tool that provides information 
about the contamination of the transplanted organ, whether 
transmitted by the donor or secondary to the transplant pro-
cedure. Preemptive antibiotic therapy for SOT recipients with 
high-risk culture-positive PF may be useful to avoid preser-
vation fluid–related infections and to improve the outcomes 
of infection, graft loss, and acute graft rejection in transplant 
patients. Further studies are required to establish the optimal 
length of PE-T days and long-term outcomes.
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Figure 1. Cumulative incidence of infection on solid organ transplant recipients depending on the result of the preservation fluid culture and the decision to carry out PE-T. 
Abbreviations: CN, culture-negative preservation fluid; PE-T, preemptive antibiotic therapy.
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